Neurological Evaluation of Toxic Axonopathies in Rats: Acrylamide and 2,5-Hexanedione
Tóm tắt
Từ khóa
Tài liệu tham khảo
Anthony, 1983, The effects of 3,4-dimethylsubstitution on the neurotoxicity of 2,5-hexanedione. Part I. Accelerated clinical neuropathy is accompanied by more proximal axonal swellings, Toxicol. Appl. Pharmacol., 71, 362
Asbury AK, Brown MJ. The evolution of structural changes in distal axonopathy. In: Spencer PS, Schaumburg HH, editors. Experimental and clinical neurotoxicology, 1st ed. Baltimore, MD: Williams & Wilkins Co., 1980. p. 179–92.
Barber, 2001, Metabolism, toxicokinetics and hemoglobin adduct formation in rats following subacute and subchronic acrylamide dosing, Neurotoxicology, 22, 341, 10.1016/S0161-813X(01)00024-9
Burek, 1980, Subchronic toxicity of acrylamide administered to rats in drinking water followed by up to 144 days of recovery, J. Environ. Pathol. Toxicol., 4, 157
Chiu, 2000, γ-Diketone peripheral neuropathy. Part II. Neurofilament subunit content, Toxicol. Appl. Pharmacol., 165, 141, 10.1006/taap.2000.8938
Crofton, 1996, The impact of dose-rate on the neurotoxicity of acrylamide: the interaction of administered dose, target tissue concentrations, tissue damage, and functional effects, Toxicol. Appl. Pharmacol., 139, 163, 10.1006/taap.1996.0155
DeCaprio AP. n-Hexane, metabolites, and derivatives. In: Spencer PS, Schaumburg HH, Ludolph AC, editors. Experimental and clinical neurotoxicology. New York: Oxford University Press, 2000. p. 633–48.
Edwards, 1977, A simple, sensitive and objective method for early assessment of acrylamide neuropathy in rats, Toxicol. Appl. Pharmacol., 40, 589, 10.1016/0041-008X(77)90083-7
Gill JL. Design and analysis of experiments in the animal and medical sciences. Ames, IA: Iowa State University Press, 1978.
Graham, 1995, Pathogenetic studies of hexane and carbon disulfide neurotoxicity, Crit. Rev. Toxicol., 25, 91, 10.3109/10408449509021609
Jakobsen, 1982, Chemical and electrophysiological characteristics of the experimental neuropathy caused by p-bromophenylacetylurea, Exp. Neurol., 75, 158, 10.1016/0014-4886(82)90015-2
Kuperman, 1958, Effects of acrylamide on the central nervous system of the cat, J. Pharmacol. Exp. Ther., 123, 180
Lehning, 1995, Axonal atrophy is a specific component of 2,5-hexanedione peripheral neuropathy, Toxicol. Appl. Pharmacol., 135, 58, 10.1006/taap.1995.1208
Lehning, 1998, Biochemical and morphologic characterization of acrylamide peripheral neuropathy, Toxicol. Appl. Pharmacol., 151, 211, 10.1006/taap.1998.8464
Lehning, 2000, γ-Diketone peripheral neuropathy. Part I. Quantitative morphometric analyses of axonal atrophy and swelling, Toxicol. Appl. Pharmacol., 165, 127, 10.1006/taap.2000.8937
Lehning, 2001, Subacute acrylamide (ACR) exposure causes widespread synaptic terminal and cerebellar Purkinje cell degeneration in rat brain, Toxicologist, 60, 366
LoPachin, 1994, Acrylamide-induced distal axon degeneration: a proposed mechanism of action, Neurotoxicology, 15, 247
LoPachin, 1997, The relevance of axonal swellings and atrophy to γ-diketone neurotoxicity: a forum position paper, Neurotoxicology, 18, 7
LoPachin, 1997, Mechanism of calcium entry during axon injury and degeneration, Toxicol. Appl. Pharmacol., 143, 233, 10.1006/taap.1997.8106
LoPachin, 2000, Rate of neurotoxicant exposure determines morphologic manifestations of distal axonopathy, Toxicol. Appl. Pharmacol., 167, 75, 10.1006/taap.2000.8984
LoPachin RM, Ross JF, Lehning EJ. Nerve terminals as the primary site of acrylamide action: a hypothesis. Neurotoxicology, 2001, in press.
Mattsson, 1996, A performance standard for clinical and functional observational battery examination of rats, J. Am. Coll. Toxicol., 15, 239, 10.3109/10915819609008716
Miller, 1985, The mechanism of acrylamide axonopathy, Ann. Rev. Pharmacol. Toxicol., 25, 643, 10.1146/annurev.pa.25.040185.003235
Moser, 1988, Comparison of chlordime form and carbaryl using a functional observational battery, Fundam. Appl. Toxicol., 11, 189, 10.1016/0272-0590(88)90144-3
Moser, 1989, Screening approaches to neurotoxicity: a functional observational battery, J. Am. Coll. Toxicol., 8, 85, 10.3109/10915818909009095
Moser, 1992, Comparison of subchronic neurotoxicity of 2-hydroxyethyl acrylate and acrylamide in rats, Fundam. Appl. Toxicol., 18, 343, 10.1016/0272-0590(92)90132-2
Meyer, 1979, A method for the routine assessment of fore- and hindlimb grip strength of rats and mice, Neurobehav. Toxicol., 1, 233
Oliver JE, Lorenz MD. Neurologic examination. In: Handbook of veterinary neurologic diagnosis. Philadelphia: Saunders, 1983. p. 19–57.
Opanashuk, 2001, γ-Diketone peripheral neuropathy. Part III. Neurofilament gene expression, Neurotoxicology, 22, 215, 10.1016/S0161-813X(00)00011-5
Pellis, 1987, Pharmacological subtraction of the sensory controls over grasping in rats, Physiol. Behav., 39, 127, 10.1016/0031-9384(87)90409-4
Ross, 1997, Quantification of the hindlimb extensor thrust response in rats, Neurotoxicol. Teratol., 19, 405, 10.1016/S0892-0362(97)00044-5
Sabri MI, Spencer PS. Toxic distal axonopathy: biochemical studies and hypothetical mechanisms. In: Spencer PS, Schaumburg HH, editors. Experimental and clinical neurotoxicology. Baltimore, MD: Williams & Wilkins Co., 1980. p. 206–19.
Schulze, 1991, A neurotoxicity screening battery for use in safety evaluation: effects of acrylamide and 3′,3′-iminodipropionitrile, Fundam. Appl. Toxicol., 16, 602, 10.1016/0272-0590(91)90099-P
Shell, 1992, Neurotoxicity of acrylamide and 2,5-hexanedione in rats evaluated using a functional observational battery and pathological examination, Neurotoxicol. Teratol., 14, 273, 10.1016/0892-0362(92)90007-W
Sills, 2000, Characterization of carbon disulfide neurotoxicity in C57BL6 mice: behavioral, morphologic and molecular effects, Toxicol. Pathol., 28, 142, 10.1177/019262330002800118
Snyder, 1977, Preliminary neurological evaluation of generalized weakness in zinc pyrithione-treated rats, Fd Cosmet. Toxicol., 15, 43, 10.1016/S0015-6264(77)80262-9
Spencer, 1974, A review of acrylamide neurotoxicity. Part I. Properties, uses and human exposure, Can. J. Neurol. Sci., 1, 151, 10.1017/S0317167100019739
Spencer, 1974, A review of acrylamide neurotoxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms, Can. J. Neurol. Sci., 1, 170, 10.1017/S0317167100119201
Spencer, 1977, Ultrastructural studies of the dying-back process. Part III. The evolution of experimental peripheral giant axonal degeneration, J. Neuropathol. Exp. Neurol., 36, 276, 10.1097/00005072-197703000-00005
Spencer, 1977, Ultrastructural studies of the dying-back process. Part IV. Differential vulnerability of PNS and CSN fibers in experimental central-peripheral distal axonopathies, J. Neuropathol. Exp. Neurol., 36, 300, 10.1097/00005072-197703000-00006
Spencer, 1979, Clinical and experimental studies of distal axonopathy—a frequent form of brain and nerve damage produced by environmental chemical hazards, New York Acad. Sci., 329, 14, 10.1111/j.1749-6632.1979.tb15331.x
Spencer, 1980, The enlarging view of hexacarbon neurotoxicity, CRC Crit. Rev. Toxicol., 7, 279, 10.3109/10408448009037489
Thompson PD, Marsden, CD. Walking disorders. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. Boston, MA: Butterworth-Heinemann, 1996. p. 477–98.